| 1. |
- Kanai, M, et al.
(author)
-
- 2023
-
swepub:Mat__t
|
|
| 2. |
- Niemi, MEK, et al.
(author)
-
- 2021
-
swepub:Mat__t
|
|
| 3. |
- Glasbey, JC, et al.
(author)
-
- 2021
-
swepub:Mat__t
|
|
| 4. |
|
|
| 5. |
|
|
| 6. |
|
|
| 7. |
|
|
| 8. |
|
|
| 9. |
- Lawrenson, Kate, et al.
(author)
-
Functional mechanisms underlying pleiotropic risk alleles at the 19p13.1 breast-ovarian cancer susceptibility locus
- 2016
-
In: Nature Communications. - : Springer Science and Business Media LLC. - 2041-1723. ; 7
-
Journal article (peer-reviewed)abstract
- A locus at 19p13 is associated with breast cancer (BC) and ovarian cancer (OC) risk. Here we analyse 438 SNPs in this region in 46,451 BC and 15,438 OC cases, 15,252 BRCA1 mutation carriers and 73,444 controls and identify 13 candidate causal SNPs associated with serous OC (P=9.2 × 10-20), ER-negative BC (P=1.1 × 10-13), BRCA1-associated BC (P=7.7 × 10-16) and triple negative BC (P-diff=2 × 10-5). Genotype-gene expression associations are identified for candidate target genes ANKLE1 (P=2 × 10-3) and ABHD8 (P<2 × 10-3). Chromosome conformation capture identifies interactions between four candidate SNPs and ABHD8, and luciferase assays indicate six risk alleles increased transactivation of the ADHD8 promoter. Targeted deletion of a region containing risk SNP rs56069439 in a putative enhancer induces ANKLE1 downregulation; and mRNA stability assays indicate functional effects for an ANKLE1 3′-UTR SNP. Altogether, these data suggest that multiple SNPs at 19p13 regulate ABHD8 and perhaps ANKLE1 expression, and indicate common mechanisms underlying breast and ovarian cancer risk.
|
|
| 10. |
|
|
| 11. |
|
|
| 12. |
|
|
| 13. |
|
|
| 14. |
|
|
| 15. |
- Van der Kolk, W. L., et al.
(author)
-
Unilateral inguinofemoral lymphadenectomy in patients with early-stage vulvar squamous cell carcinoma and a unilateral metastatic sentinel lymph node is safe
- 2022
-
In: Gynecologic Oncology. - : Elsevier BV. - 0090-8258 .- 1095-6859. ; 167:1, s. 3-10
-
Journal article (peer-reviewed)abstract
- Objective. Optimal management of the contralateral groin in patients with early-stage vulvar squamous cell carcinoma (VSCC) and a metastatic unilateral inguinal sentinel lymph node (SN) is unclear. We analyzed patients who participated in GROINSS-V I or II to determine whether treatment of the contralateral groin can safely be omitted in patients with a unilateral metastatic SN.Methods. We selected the patients with a unilateral metastatic SN from the GROINSS-V I and II databases. We determined the incidence of contralateral additional non-SN metastases in patients with unilateral SN-metastasis who underwent bilateral inguinofemoral lymphadenectomy (IFL). In those who underwent only ipsilateral groin treatment or no further treatment, we determined the incidence of contralateral groin recurrences during follow-up.Results. Of 1912 patients with early-stage VSCC, 366 had a unilateral metastatic SN. Subsequently, 244 had an IFL or no treatment of the contralateral groin. In seven patients (7/244; 2.9% [95% CI: 1.4%-5.8%]) disease was di-agnosed in the contralateral groin: five had contralateral non-SN metastasis at IFL and two developed an isolated contralateral groin recurrence after no further treatment. Five of them had a primary tumor >= 30 mm. Bilateral ra-diotherapy was administered in 122 patients, of whom one (1/122; 0.8% [95% CI: 0.1%-4.5%]) had a contralateral groin recurrence.Conclusion. The risk of contralateral lymph node metastases in patients with early-stage VSCC and a unilateral metastatic SN is low. It appears safe to limit groin treatment to unilateral IFL or inguinofemoral radiotherapy in these cases.(c) 2022 The Authors. Published by Elsevier Inc. This is an open access article under the CC BY license (http:// creativecommons.org/licenses/by/4.0/).
|
|
| 16. |
- Cockell, C.S., et al.
(author)
-
Habitability : a review
- 2016
-
In: Astrobiology. - : Mary Ann Liebert Inc. - 1531-1074 .- 1557-8070. ; 16:1, s. 89-117
-
Journal article (peer-reviewed)abstract
- Habitability is a widely used word in the geoscience, planetary science, and astrobiology literature, but what does it mean? In this review on habitability, we define it as the ability of an environment to support the activity of at least one known organism. We adopt a binary definition of “habitability” and a “habitable environment.” An environment either can or cannot sustain a given organism. However, environments such as entire planets might be capable of supporting more or less species diversity or biomass compared with that of Earth. A clarity in understanding habitability can be obtained by defining instantaneous habitability as the conditions at any given time in a given environment required to sustain the activity of at least one known organism, and continuous planetary habitability as the capacity of a planetary body to sustain habitable conditions on some areas of its surface or within its interior over geological timescales. We also distinguish between surface liquid water worlds (such as Earth) that can sustain liquid water on their surfaces and interior liquid water worlds, such as icy moons and terrestrial-type rocky planets with liquid water only in their interiors. This distinction is important since, while the former can potentially sustain habitable conditions for oxygenic photosynthesis that leads to the rise of atmospheric oxygen and potentially complex multicellularity and intelligence over geological timescales, the latter are unlikely to. Habitable environments do not need to contain life. Although the decoupling of habitability and the presence of life may be rare on Earth, it may be important for understanding the habitability of other planetary bodies
|
|
| 17. |
- Oonk, M. H. M., et al.
(author)
-
Radiotherapy Versus Inguinofemoral Lymphadenectomy as Treatment for Vulvar Cancer Patients With Micrometastases in the Sentinel Node: Results of GROINSS-V II
- 2021
-
In: Journal of Clinical Oncology. - : American Society of Clinical Oncology (ASCO). - 0732-183X .- 1527-7755. ; 39:32
-
Journal article (peer-reviewed)abstract
- PURPOSE The Groningen International Study on Sentinel nodes in Vulvar cancer (GROINSS-V)-II investigated whether inguinofemoral radiotherapy is a safe alternative to inguinofemoral lymphadenectomy (IFL) in vulvar cancer patients with a metastatic sentinel node (SN). METHODS GROINSS-V-II was a prospective multicenter phase-II single-arm treatment trial, including patients with early-stage vulvar cancer (diameter < 4 cm) without signs of lymph node involvement at imaging, who had primary surgical treatment (local excision with SN biopsy). Where the SN was involved (metastasis of any size), inguinofemoral radiotherapy was given (50 Gy). The primary end point was isolated groin recurrence rate at 24 months. Stopping rules were defined for the occurrence of groin recurrences. RESULTS From December 2005 until October 2016, 1,535 eligible patients were registered. The SN showed metastasis in 322 (21.0%) patients. In June 2010, with 91 SN-positive patients included, the stopping rule was activated because the isolated groin recurrence rate in this group went above our predefined threshold. Among 10 patients with an isolated groin recurrence, nine had SN metastases > 2 mm and/or extracapsular spread. The protocol was amended so that those with SN macrometastases (> 2 mm) underwent standard of care (IFL), whereas patients with SN micrometastases (<= 2 mm) continued to receive inguinofemoral radiotherapy. Among 160 patients with SN micrometastases, 126 received inguinofemoral radiotherapy, with an ipsilateral isolated groin recurrence rate at 2 years of 1.6%. Among 162 patients with SN macrometastases, the isolated groin recurrence rate at 2 years was 22% in those who underwent radiotherapy, and 6.9% in those who underwent IFL (P = .011). Treatment-related morbidity after radiotherapy was less frequent compared with IFL. CONCLUSION Inguinofemoral radiotherapy is a safe alternative for IFL in patients with SN micrometastases, with minimal morbidity. For patients with SN macrometastasis, radiotherapy with a total dose of 50 Gy resulted in more isolated groin recurrences compared with IFL. (C) 2021 by American Society of Clinical Oncology
|
|
| 18. |
|
|
| 19. |
|
|
| 20. |
- Gautier, S., et al.
(author)
-
AlGaN/AlN multiple quantum wells grown by MOVPE on AlN templates using nitrogen as a carrier gas
- 2008
-
In: Journal of Crystal Growth. - : Elsevier BV. - 0022-0248 .- 1873-5002. ; 310:23, s. 4927-4931
-
Journal article (peer-reviewed)abstract
- AlxGa1-xN/AlN multiple quantum wells (MQWs) structures were grown by metalorganic vapour phase epitaxy (MOVPE) on pseudo AlN substrates using nitrogen as a carrier gas. Results of X-ray diffraction (XRD) and reciprocal space mapping (RSM) indicated no sign of strain relaxation in the quantum wells with respect to the AlN substrate. The MQW parameters such as thicknesses, growth rates and material compositions were extracted from XRD measurements and demonstrated an agreement with our growth conditions. No indication of parasitic reactions between ammonia and trimethyl-aluminium (TMAI) was detected in our growth process. Optical measurements revealed well-defined photoluminescence peaks at 288 and 280 nm, which are in a good agreement with the transmission experimental data. The piezoelectric field value in the Studied structures was estimated to be 900kV/cm.
|
|
| 21. |
|
|
| 22. |
- Oonk, Maaike H. M., et al.
(author)
-
Radiotherapy Versus Inguinofemoral Lymphadenectomy as Treatment for Vulvar Cancer Patients With Micrometastases in the Sentinel Node : Results of GROINSS-V II
- 2021
-
In: Journal of Clinical Oncology. - : Lippincott, Williams & Wilkins. - 0732-183X .- 1527-7755. ; 39:32, s. 3623-3632
-
Journal article (peer-reviewed)abstract
- PURPOSE The Groningen International Study on Sentinel nodes in Vulvar cancer (GROINSS-V)-II investigated whether inguinofemoral radiotherapy is a safe alternative to inguinofemoral lymphadenectomy (IFL) in vulvar cancer patients with a metastatic sentinel node (SN). METHODS GROINSS-V-II was a prospective multicenter phase-II single-arm treatment trial, including patients with early-stage vulvar cancer (diameter < 4 cm) without signs of lymph node involvement at imaging, who had primary surgical treatment (local excision with SN biopsy). Where the SN was involved (metastasis of any size), inguinofemoral radiotherapy was given (50 Gy). The primary end point was isolated groin recurrence rate at 24 months. Stopping rules were defined for the occurrence of groin recurrences. RESULTS From December 2005 until October 2016, 1,535 eligible patients were registered. The SN showed metastasis in 322 (21.0%) patients. In June 2010, with 91 SN-positive patients included, the stopping rule was activated because the isolated groin recurrence rate in this group went above our predefined threshold. Among 10 patients with an isolated groin recurrence, nine had SN metastases > 2 mm and/or extracapsular spread. The protocol was amended so that those with SN macrometastases (> 2 mm) underwent standard of care (IFL), whereas patients with SN micrometastases (<= 2 mm) continued to receive inguinofemoral radiotherapy. Among 160 patients with SN micrometastases, 126 received inguinofemoral radiotherapy, with an ipsilateral isolated groin recurrence rate at 2 years of 1.6%. Among 162 patients with SN macrometastases, the isolated groin recurrence rate at 2 years was 22% in those who underwent radiotherapy, and 6.9% in those who underwent IFL (P = .011). Treatment-related morbidity after radiotherapy was less frequent compared with IFL. CONCLUSION Inguinofemoral radiotherapy is a safe alternative for IFL in patients with SN micrometastases, with minimal morbidity. For patients with SN macrometastasis, radiotherapy with a total dose of 50 Gy resulted in more isolated groin recurrences compared with IFL.
|
|
| 23. |
|
|
| 24. |
- Alshaykh, Mohammed S., et al.
(author)
-
Optical dual-comb Vernier division of an octave-spanning Kerr microcomb
- 2021
-
In: 2021 Conference on Lasers and Electro-Optics, CLEO 2021 - Proceedings.
-
Conference paper (peer-reviewed)abstract
- We measure the repetition rate of a 900 GHz octave-spanning soliton microcomb based on Vernier dual-comb frequency division implemented with two silicon nitride microresonator combs fabricated on the same wafer.
|
|
| 25. |
- Bazilian, M., et al.
(author)
-
Accelerating the global transformation to 21st century power systems
- 2013
-
In: Electricity Journal. - : Elsevier BV. - 1040-6190 .- 1873-6874. ; 26:6, s. 39-51
-
Journal article (peer-reviewed)abstract
- Nations and regions need to share lessons about the best ways to create enabling policies, regulations, and markets that get the most social benefit out of power systems and incent the necessary investments.
|
|
| 26. |
|
|
| 27. |
|
|
| 28. |
|
|
| 29. |
- Monk, Bradley J., et al.
(author)
-
A Randomized, Phase III Trial to Evaluate Rucaparib Monotherapy as Maintenance Treatment in Patients With Newly Diagnosed Ovarian Cancer (ATHENA-MONO/GOG-3020/ENGOT-ov45)
- 2022
-
In: Journal of Clinical Oncology. - : Lippincott, Williams & Wilkins. - 0732-183X .- 1527-7755. ; 40:34, s. 3952-3964
-
Journal article (peer-reviewed)abstract
- PURPOSEATHENA (ClinicalTrials.gov identifier: ) was designed to evaluate rucaparib first-line maintenance treatment in a broad patient population, including those without BRCA1 or BRCA2 (BRCA) mutations or other evidence of homologous recombination deficiency (HRD), or high-risk clinical characteristics such as residual disease. We report the results from the ATHENA-MONO comparison of rucaparib versus placebo.METHODSPatients with stage III-IV high-grade ovarian cancer undergoing surgical cytoreduction (R0/complete resection permitted) and responding to first-line platinum-doublet chemotherapy were randomly assigned 4:1 to oral rucaparib 600 mg twice a day or placebo. Stratification factors were HRD test status, residual disease after chemotherapy, and timing of surgery. The primary end point of investigator-assessed progression-free survival was assessed in a step-down procedure, first in the HRD population (BRCA-mutant or BRCA wild-type/loss of heterozygosity high tumor), and then in the intent-to-treat population.RESULTSAs of March 23, 2022 (data cutoff), 427 and 111 patients were randomly assigned to rucaparib or placebo, respectively (HRD population: 185 v 49). Median progression-free survival (95% CI) was 28.7 months (23.0 to not reached) with rucaparib versus 11.3 months (9.1 to 22.1) with placebo in the HRD population (log-rank P = .0004; hazard ratio [HR], 0.47; 95% CI, 0.31 to 0.72); 20.2 months (15.2 to 24.7) versus 9.2 months (8.3 to 12.2) in the intent-to-treat population (log-rank P < .0001; HR, 0.52; 95% CI, 0.40 to 0.68); and 12.1 months (11.1 to 17.7) versus 9.1 months (4.0 to 12.2) in the HRD-negative population (HR, 0.65; 95% CI, 0.45 to 0.95). The most common grade & GE; 3 treatment-emergent adverse events were anemia (rucaparib, 28.7% v placebo, 0%) and neutropenia (14.6% v 0.9%).CONCLUSIONRucaparib monotherapy is effective as first-line maintenance, conferring significant benefit versus placebo in patients with advanced ovarian cancer with and without HRD.
|
|
| 30. |
- O'Malley, Elissa, et al.
(author)
-
The presence of selected UV filters in a freshwater recreational reservoir and fate in controlled experiments
- 2021
-
In: Science of the Total Environment. - : Elsevier BV. - 0048-9697 .- 1879-1026. ; 754
-
Journal article (peer-reviewed)abstract
- UV filters present in sunscreen and other cosmetics are directly released into the environment during aquatic recreational activities. The extent to which the wide range of UV filters pose a risk to the environment remains unclear. This study investigated the occurrence and dissipation of selected organic UV filters at a recreational site (Enoggera Reservoir, Queensland, Australia) over 12 h. Furthermore, different possible degradation processes were investigated in a controlled off-site experiment with surface water exposed to natural light. Half-lives were estimated for ten UV filters. In Enoggera Reservoir, seven UV filters were detected, of which the most prevalent were octocrylene, avobenzone (BMDBM) and enzacamene (4-MBC). Summed concentrations of the seven UV filters ranged from 7330 ng L-1 at 13:00 h to 2550 ng L-1 at 21:00 h. In the degradation experiment, four UV filters showed no significant change over time. The fate of these compounds in the environment is likely to be mainly influenced by dispersion. Half-lives of the remaining UV filters were 6.6 h for amiloxate (IMC), 20 h for benzophenone 1, 23 h for octinoxate (EHMC), 30 h for 3-benzylidene camphor, 34 h for 4-MBC and 140 h for dioxybenzone (BP8). The degree of susceptibility to photodegradation and biodegradation was generally consistent within a structural class. The fate and half-lives of UV filters are variable and should be considered on a per site basis when assessing environmental risk.
|
|
| 31. |
- O'Malley, Nathan P., et al.
(author)
-
RF Stabilization of Vernier Dual-microcombs
- 2023
-
In: 2023 Conference on Lasers and Electro-Optics, CLEO 2023.
-
Conference paper (peer-reviewed)abstract
- Leveraging the Vernier dual-comb method, we self-reference a THz octave-spanning microcomb with fCEO ~100 GHz - normally too high for typical detection equipment - and translate the stability of an RF reference to optical frequencies.
|
|
| 32. |
- O'Malley, Nathan P., et al.
(author)
-
Vernier Frequency Combs for Stabilization of RF/Optical Links
- 2022
-
In: Optics InfoBase Conference Papers. - 9781957171050
-
Conference paper (peer-reviewed)abstract
- We utilize the Vernier effect to partially stabilize a pair of high repetition rate, octave-spanning Kerr solitons in silicon nitride microrings fabricated on the same wafer.
|
|
| 33. |
- O'Malley, Nathan P., et al.
(author)
-
Vernier Microcombs for Future Miniature Yb + Clocks
- 2023
-
In: 2023 IEEE Photonics Conference, IPC 2023 - Proceedings.
-
Conference paper (peer-reviewed)abstract
- We demonstrate an architecture for dualmicrocomb-based readout of an optical clock. Microcombs frequency-divide a compact narrow-linewidth laser, capable of being frequency-doubled to within a few GHz of a 171Yb+ clock transition, to an RF output.
|
|
| 34. |
|
|
| 35. |
- Porter, A. J., et al.
(author)
-
The effect of Si/Al ratio on local and nanoscale water diffusion in H-ZSM-5: A quasielastic neutron scattering and molecular dynamics simulation study
- 2023
-
In: Microporous and Mesoporous Materials. - : Elsevier BV. - 1387-1811. ; 348
-
Journal article (peer-reviewed)abstract
- The dynamics of water confined in H-ZSM-5 (protonated form of the Zeolite Socony Mobil – 5) has been studied using quasielastic neutron scattering (QENS) and classical molecular dynamics simulations (MD). QENS measurements probed water confined in ZSM-5 samples with Si/Al ratios of 15, 40 and 140 at 2.8 wt% loadings. In the lower silica samples, fitting of the elastic incoherent structure factor (EISF) showed that water diffusion was confined to a sphere (with radii ranging from 3.4 to 4.3 Å), suggesting the mobile water was located within the MFI (framework type of H-ZSM-5) channel intersections, giving localised diffusion coefficients in the range of ∼0.9–1.8 × 10−9 m2s−1. In the high silica zeolite, the diffusion was observed to be far less confined and more long range in nature, with diffusion coefficients significantly higher than in the lower silica systems (∼1.8–4.8 × 10−9 m2s−1). MD simulations further investigated the effect of the Si/Al ratio on water diffusivity at 2.8 wt% loading (9 molecules/unit cell (UC)) in H-ZSM-5 with Si/Al ratio = 15, 47, 95 and fully siliceous. The Si/Al ratio had a significant effect on the MD calculated nanoscale diffusivity of water, reducing the self-diffusion coefficient by a factor of 2 from a fully siliceous system to that with Si/Al = 15, due to the strong coordination and increased residence time of water molecules at the Brønsted acid sites which range from ∼5 ps to ∼2 ps in the Si/Al = 15 and Si/Al = 95 systems respectively. QENS observables, both the EISF and quasielastic line broadenings, were reproduced from the MD trajectories upon sampling the experimental timescale giving both qualitative and quantitative agreement with the QENS experiments. Fitting of the MD calculated EISF showed that the experimentally observed diffusion confined to a sphere of radii ranging from 3.5 to 6.8 Å was also present in our simulations, with diffusion coefficients calculated to within a factor of 0.5 of experiment.
|
|
| 36. |
- Rubins, Daniel J., et al.
(author)
-
In Vivo Evaluation and Dosimetry Estimate for a High Affinity Affibody PET Tracer Targeting PD-L1
- 2021
-
In: Molecular Imaging and Biology. - : Springer. - 1536-1632 .- 1860-2002. ; 23, s. 241-249
-
Journal article (peer-reviewed)abstract
- Purpose: In vivo imaging of programmed death ligand 1 (PD-L1) during immunotherapy could potentially monitor changing PD-L1 expression and PD-L1 expression heterogeneity within and across tumors. Some protein constructs can be used for same-day positron emission tomography (PET) imaging. Previously, we evaluated the PD-L1-targeting Affibody molecule [F-18]AlF-NOTA-Z(PD-L1_1) as a PET tracer in a mouse tumor model of human PD-L1 expression. In this study, we evaluated the affinity-matured Affibody molecule Z(PD-L1_4), to determine if improved affinity for PD-L1 resulted in increased in vivo targeting of PD-L1.Procedures: Z(PD-L1_4) was conjugated with NOTA and radiolabeled with either [F-18]AlF or Ga-68. [F-18]AlF-NOTA-Z(PD-L1_4) and [Ga-68]NOTA-Z(PD-L1_4) were evaluated in immunocompromised mice with LOX (PD-L1+) and SUDHL6 (PD-L1-) tumors with PET and ex vivo biodistribution measurements. In addition, whole-body PET studies were performed in rhesus monkeys to predict human biodistribution in a model with tracer binding to endogenous PD-L1, and to calculate absorbed radiation doses.Results: Ex vivo biodistribution measurements showed that both tracers had > 25 fold higher accumulation in LOX tumors than SUDHL6 ([F-18]AlF-NOTA-Z(PD-L1_4): LOX: 8.7 +/- 0.7 %ID/g (N = 4) SUDHL6: 0.2 +/- 0.01 %ID/g (N = 6), [Ga-68]NOTA-Z(PD-L1_4): LOX: 15.8 +/- 1.0 %ID/g (N = 6) SUDHL6: 0.6 +/- 0.1 %ID/g (N = 6)), considerably higher than Z(PD-L1_1). In rhesus monkeys, both PET tracers showed fast clearance through kidneys and low background signal in the liver ([F-18]AlF-NOTA-Z(PD-L1_4): 1.26 +/- 0.13 SUV, [Ga-68]NOTA-Z(PD-L1_4): 1.11 +/- 0.06 SUV). PD-L1-expressing lymph nodes were visible in PET images, indicating in vivo PD-L1 targeting. Dosimetry estimates suggest that both PET tracers can be used for repeated clinical studies, although high kidney accumulation may limit allowable radioactive doses.Conclusions: [F-18]AlF-NOTA-Z(PD-L1_4) and [Ga-68]NOTA-Z(PD-L1_4) are promising candidates for same-day clinical PD-L1 PET imaging, warranting clinical evaluation. The ability to use either [F-18] or [Ga-68] may expand access to clinical sites.
|
|
| 37. |
- Trotter, Dinko E. Gonzalez, et al.
(author)
-
In Vivo Imaging of the Programmed Death Ligand 1 by F-18 PET
- 2017
-
In: Journal of Nuclear Medicine. - : Society of Nuclear Medicine. - 0161-5505 .- 1535-5667 .- 2159-662X. ; 58:11, s. 1852-1857
-
Journal article (peer-reviewed)abstract
- Programmed death ligand 1 (PD-L1) is an immune regulatory ligand that binds to the T-cell immune check point programmed death 1. Tumor expression of PD-L1 is correlated with immune suppression and poor prognosis. It is also correlated with therapeutic efficacy of programmed death 1 and PD-L1 inhibitors. In vivo imaging may enable real-time follow-up of changing PD-L1 expression and heterogeneity evaluation of PD-L1 expression across tumors in the same subject. We have radiolabeled the PD-L1-binding Affibody molecule NOTA-Z(PD-L1_1) with F-18 and evaluated its in vitro and in vivo binding affinity, targeting, and specificity. Methods: The affinity of the PD-L1-binding Affibody ligand Z(PD-L1_1) was evaluated by surface plasmon resonance. Labeling was accomplished by maleimide coupling of NOTA to a unique cysteine residue and chelation of F-18-AlF. In vivo studies were performed in PD-L1-positive, PD-L1-negative, and mixed tumor-bearing severe combined immunodeficiency mice. Tracer was injected via the tail vein, and dynamic PET scans were acquired for 90 min, followed by gamma-counting biodistribution. Immunohistochemical staining with an antibody specific for anti-PD-L1 (22C3) was used to evaluate the tumor distribution of PD-L1. Immunohistochemistry results were then compared with ex vivo autoradiographic images obtained from adjacent tissue sections. Results: NOTA-Z(PD-L1_1) was labeled, with a radiochemical yield of 15.1% +/- 5.6%, radiochemical purity of 96.7% +/- 2.0%, and specific activity of 14.6 +/- 6.5 GBq/mu mol. Surface plasmon resonance showed a NOTA-conjugated ligand binding affinity of 1 nM. PET imaging demonstrated rapid uptake of tracer in the PD-L1-positive tumor, whereas the PD-L1-negative control tumor showed little tracer retention. Tracer clearance from most organs and blood was quick, with biodistribution showing prominent kidney retention, low liver uptake, and a significant difference between PD-L1-positive (percentage injected dose per gram [%ID/g] = 2.56 +/- 0.33) and -negative (% ID/g = 0.32 +/- 0.05) tumors (P = 0.0006). Ex vivo autoradiography showed excellent spatial correlation with immunohistochemistry in mixed tumors. Conclusion: Our results show that Affibody ligands can be effective at targeting tumor PD-L1 in vivo, with good specificity and rapid clearance. Future studies will explore methods to reduce kidney activity retention and further increase tumor uptake.
|
|
| 38. |
|
|
| 39. |
|
|
| 40. |
|
|
| 41. |
- Wu, Kaiyi, et al.
(author)
-
Vernier microcombs for high-frequency carrier envelope offset and repetition rate detection
- 2023
-
In: Optica. - 2334-2536. ; 10:5, s. 626-633
-
Journal article (peer-reviewed)abstract
- Recent developments in Kerr microcombs may pave the way to a future with fully stabilized ultralow size, weight, and power consumption (SWaP) frequency combs. Nevertheless, Kerr microcombs are still hindered by a band-width/repetition rate trade-off. That is, the octave bandwidth needed for self-referencing is typically realized only with similar to THz repetition rates beyond the range of standard commercial photodetectors. The carrier envelope offset fre-quency fCEO is often likewise too high for detection. Dual-comb techniques for the measurement of THz repetition rates have made exciting progress, but the fCEO detection problem remains largely unaddressed. In this work, utilizing a Vernier dual-comb configuration, we demonstrate simultaneous detection of the electronically divided similar to 900 GHz rep-etition rate and similar to 97 GHz carrier envelope offset frequency of an octave-spanning microcomb. This, in turn, could help usher optical atomic clocks, low-noise microwave generators, and optical frequency synthesizers into various real-world applications.Published by Optica Publishing Group under the terms of the Creative Commons Attribution 4.0 License. Further distribution of this work must maintain attribution to the author(s) and the published article's title, journal citation, and DOI.
|
|
